by Raynovich Rod | Jun 11, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
New technologies in diagnostics and tools are driving growth: NexGen sequencing, molecular and “point-of-care” testing platforms and veterinary testing. M&A and consolidation should continue. The sector is a laggard due to slowing sales and earnings...
by Raynovich Rod | Apr 21, 2015 | Biopharmaceuticals
Update ILMN 12n EDT trading 4/22 Illumina (ILMN) is selling off from the opening and is now down 4.8% on heavy volume of over 2M shares. The stock has a high PE of 83, P/S of 15 and 95% institutional holdings. Profit taking is underway. The chart shows a triple top at...
by Raynovich Rod | Mar 12, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Diagnostic Stocks rally with NASDAQ and Small Caps -IWM Up 1.66% Life Science Tools and Diagnostics stocks are a tad off their one year highs hit by dollar strength and disappointing revenue growth in some cases. Sequencing stocks were big winners but sold off after...
by Raynovich Rod | Jan 29, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Solid earnings reports-All of Our Picks Are Strong Holds But Strong Dollar a Factor in 2105 Cardiovascular Systems (CSII) Stock Soars 15% On Strong Revenues Interventional treatments for cardiovascular disease Q2 Revenues soared 38% to $44.7M compared to previous...
by Raynovich Rod | Jan 19, 2015 | Biopharmaceuticals, Clinical Diagnostics and Tools
Seminar: Harnessing the Power of Next Gen Sequencing: The View from Industry 1/12/15 A panel of leading entrepreneurial R&D executives presented their outlook and issues on the future of Next Gen Sequencing (NGS), focusing on drug development and future clinical...
by Raynovich Rod | Nov 26, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
NASDAQ leads -up 0.6% to 4787 The October correction of ~7% was a “headfake” as macro events scared many investor away Technology and Healthcare Stocks Lead The Way The healthcare SPDR (XLV) is up 24.5% YTD and the technology SPDR (XLK) is up 18% YTD....
by Raynovich Rod | Oct 31, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Investors Whipsawed By V-Shaped Rally NASDAQ at New Highs 4631 DOW at New Highs 17,390 Investors got what was forecasted-a volatile October that moved from fear to greed in two weeks! The market was buffeted by the Ebola scare, macro analysts decrying easy money from...
by Raynovich Rod | Jun 18, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update June 19.. 3:10 p EDT Ten Yr 2.62%, U.S.equities flat,biotech mixed, jobless claims down. Japanese and European equities up. Iraq on front page. GOLD Up $41 Breaks Through Resistance at $1300 Gold futures rose on technicals, Middle East turmoil, a weak dollar...
by Raynovich Rod | May 22, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Update 11/24/14 Clinical Diagnostics and Tools Stocks Review Performance YTD and compared to 11/13 YTD Top winners YTD are: EXAS 104%, ILMN 71.4%, ABAX 36.8% Top Losers YTD are: NSTG 16.6%, RGDX 54%, VRML 30.9% but all were good trades. IWM at $117.4 See Performance...
by Raynovich Rod | Mar 7, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
Diagnostics Companies-After 2013 Financial Reporting Stocks to Watch: Cepheid (CPHD), Exact Sciences (EXAS) , Orasure (OSUR) Price to Sales (P/S) is the best metric of value as many companies in the sector are not profitable. Molecular diagnostics and genomics are...